SG10201902826PA - Stable compositions of peptide epoxy ketones - Google Patents

Stable compositions of peptide epoxy ketones

Info

Publication number
SG10201902826PA
SG10201902826PA SG10201902826PA SG10201902826PA SG10201902826PA SG 10201902826P A SG10201902826P A SG 10201902826PA SG 10201902826P A SG10201902826P A SG 10201902826PA SG 10201902826P A SG10201902826P A SG 10201902826PA SG 10201902826P A SG10201902826P A SG 10201902826PA
Authority
SG
Singapore
Prior art keywords
peptide epoxy
stable compositions
epoxy ketones
ketones
peptide
Prior art date
Application number
SG10201902826PA
Inventor
Ketan Hippalgaonkar
Kumaresh Soppimath
Satish Pejaver
Navneet Puri
Original Assignee
Innopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innopharma Inc filed Critical Innopharma Inc
Publication of SG10201902826PA publication Critical patent/SG10201902826PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

STABLE COMPOSITIONS OF PEPTIDE EPOXY KETONES The invention relates to pharmaceutical compositions that provide improved solubility and stability for peptide epoxy ketones. More specifically, the invention relates to pharmaceutical compositions comprising the peptide epoxy ketone proteasorne inhibitor carfilzomib. Accordingly, in one aspect, the invention provides a lyophilized composition comprising a peptide epoxy ketone and a non-volatile sugar acid. In one embodiment, the non-volatile sugar acid is lactobionic acid. No Figure
SG10201902826PA 2013-09-10 2014-09-05 Stable compositions of peptide epoxy ketones SG10201902826PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/023,247 US9636376B2 (en) 2012-09-11 2013-09-10 Stable compositions of peptide epoxy ketones

Publications (1)

Publication Number Publication Date
SG10201902826PA true SG10201902826PA (en) 2019-04-29

Family

ID=50233867

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201605825WA SG11201605825WA (en) 2013-09-10 2014-09-05 Stable compositions of peptide epoxy ketones
SG10201902826PA SG10201902826PA (en) 2013-09-10 2014-09-05 Stable compositions of peptide epoxy ketones

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201605825WA SG11201605825WA (en) 2013-09-10 2014-09-05 Stable compositions of peptide epoxy ketones

Country Status (7)

Country Link
US (3) US9636376B2 (en)
EP (1) EP3062883A4 (en)
CA (1) CA2934859A1 (en)
EA (1) EA201691358A1 (en)
SG (2) SG11201605825WA (en)
WO (1) WO2015038431A1 (en)
ZA (1) ZA201604055B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015198257A1 (en) * 2014-06-26 2015-12-30 Intas Pharmaceuticals Ltd. Stable carfilzomib injection
WO2016110870A1 (en) * 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Pharmaceutical composition of bortezomid
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
WO2016170489A1 (en) * 2015-04-24 2016-10-27 Fresenius Kabi Oncology Ltd. Pharmaceutical compositions of proteasome inhibitor
US10098890B2 (en) * 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
WO2018138556A1 (en) * 2017-01-24 2018-08-02 Orbicular Pharmaceutical Technologies Pvt. Ltd. Non-aqueous carfilzomib compositions
GB2562270B (en) * 2017-05-10 2020-07-01 Hyphens Pharma Pte Ltd Skin barrier composition
WO2019099715A1 (en) * 2017-11-16 2019-05-23 Amgen Inc. Stable compositions of pegylated carfilzomib compounds
CN115666579A (en) * 2020-04-15 2023-01-31 卡希夫生物科学有限公司 Stable, ready-to-dilute formulations of carfilzomib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689758T2 (en) 1985-08-31 1994-08-18 Kitasato Inst Erythromycin derivative and process for its preparation.
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US20040170724A1 (en) 2003-02-28 2004-09-02 Kraft Foods Holdings, Inc. Mineral complexes of lactobionic acid and method of using for mineral fortification of food products
CN1921772B (en) 2004-02-23 2012-02-22 诺维信公司 Meat based food product comprising lactobionic acid
PT2261236E (en) 2004-12-07 2015-10-30 Onyx Therapeutics Inc Composition for proteasome inhibition
WO2008039473A2 (en) 2006-09-27 2008-04-03 Scidose Llc Alcohol free formulation of argatroban
KR20160086980A (en) * 2007-10-04 2016-07-20 오닉스 세라퓨틱스, 인크. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
CN101624412B (en) 2008-07-10 2012-07-04 刘力 Derivative of macrolides, method for preparing same and application thereof
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
US20120052097A1 (en) * 2010-08-20 2012-03-01 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
EP2810066B1 (en) 2012-01-24 2019-07-31 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
CN105163720B (en) * 2013-02-01 2019-10-11 佐尼奥尼制药股份有限公司 Remote loading sparingly water-soluble drug is to liposome

Also Published As

Publication number Publication date
US20170202901A1 (en) 2017-07-20
EP3062883A4 (en) 2017-08-16
WO2015038431A1 (en) 2015-03-19
US9636376B2 (en) 2017-05-02
EA201691358A1 (en) 2016-11-30
EP3062883A1 (en) 2016-09-07
SG11201605825WA (en) 2016-09-29
ZA201604055B (en) 2018-11-28
US20190060393A1 (en) 2019-02-28
CA2934859A1 (en) 2015-03-19
US20140073583A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
SG10201902826PA (en) Stable compositions of peptide epoxy ketones
CU20190058A7 (en) AMINO ACID COMPOSITIONS RELATED TO IMPROVEMENTS IN LIVER FUNCTION
MX2021010033A (en) Microencapsulated cannabinoid compositions.
EA201201519A1 (en) COMPLEXATION METHODS WITH CYCLODEXTRINS FOR THE INTRODUCTION OF PEPTIDE PROTEASOMIC INHIBITORS INTO PHARMACEUTICAL COMPOSITIONS
ME01277B (en) Crystalline tripeptide epoxy ketone protease inhibitors
PH12016500895A1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
MX340983B (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
MX2015011110A (en) Solid compositions comprising a glucokinase activator and methods of making and using the same.
NZ710291A (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions
BR112012032248A2 (en) 5-ethyl-2- {4 - [- 4- (-4-tetrazol-1-yl-phenoxymethyl) -thiazol-2-yl] -piperidin-1-yl} -pyrimidine compositions
WO2014137797A3 (en) Stable glucokinase activator compositions
IL243435B (en) High potery pancreatin pharmaceutical compositions
MX2016009667A (en) Crystal form a of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same.
HK1216715A1 (en) Novel hemoglobin-derived peptide based pharmaceutical compositions
MX2016001038A (en) Partial melt co-crystallization compositions.
WO2014166836A8 (en) Growth hormone compound formulation
MX2015016603A (en) Corticosteroid compositions.
MX370990B (en) Esters of oligo-hydroxycarboxylic acids and use thereof.
DK2612850T3 (en) Crystalline delta form of the arginine salt of perindopril, process for its preparation and pharmaceutical compositions containing this
IN2013MU02715A (en)
IN2013CH05858A (en)
IN2013MU01318A (en)
TH1401007694A (en) Pharmaceutical composition and treatment of mastitis (PHARMACEUTICAL COMPOSITIONS AND TREATMENT OF MASTITIS)
TH1301000018B (en) Delta crystal form of the arginine salt of perindopril. (PERINDOPRIL), process for preparing such substances and pharmaceutical compositions containing such substances
PL406248A1 (en) Pharmaceutical composition, containing docosahexaenoic acid, and its application